MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.90
-0.16
-1.77%
Closed 16:00 09/24 EDT
OPEN
9.00
PREV CLOSE
9.06
HIGH
9.13
LOW
8.80
VOLUME
179.83K
TURNOVER
--
52 WEEK HIGH
13.29
52 WEEK LOW
2.820
MARKET CAP
227.44M
P/E (TTM)
-5.4655
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Companies Like Pluristem Therapeutics (NASDAQ:PSTI) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 09/14 20:15
Pluristem Therapeutics: Behind The Massive Rally
Today, we take an in depth look at an Israeli based biotech concern. The company has several 'shots on goal', upcoming potential catalysts and significant recent purchases by a beneficial owner. A full investment analysis is presented in the paragraphs below.
Seekingalpha · 09/08 13:21
ABT, CLVS among premarket gainers
Moxian (MOXC) +52% on merger with Btab.VBI Vaccines (VBIV) +38%.ZAGG (ZAGG) +21% as InvisibleShield screen protection with exclusive partner Kastus anti-microbial technology confirmed to kill human coronavirus.ReneSola (SOL) +20% on
Seekingalpha · 08/27 12:21
Pluristem launches COVID-19 expanded access program
The FDA has cleared Pluristem Therapeutics' (PSTI) Expanded Access Program ((EAP)) for the use of its PLX-PAD cells to treat Acute Respiratory Distress Syndrome ((ARDS)) caused by COVID-19 outside of the
Seekingalpha · 08/27 12:10
Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, Enabling Patient Treatment Outside of Clinical Trial
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Expanded
GlobeNewswire · 08/27 12:00
Pluristem Announces FDA Has Cleared Co.'s Expanded Access For Use Of PLX-PAD Cells In Acute Respiratory Distress Syndrome Caused By COVID-19
HAIFA, Israel, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced
Benzinga · 08/27 11:01
Pluristem completes enrollment in early-stage study of cell therapy
Pluristem Therapeutics (PSTI) announces the full enrollment of 20 subjects in a Phase 1 clinical trial evaluating cell therapy PLX-R18 for the potential treatment for incomplete hematopoietic recovery following hematopoietic
Seekingalpha · 08/20 12:36
Pluristem Announces End of Patient Enrollment in its Phase I Hematology Study
Top line efficacy results expected Q1 2021HAIFA, Israel, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has completed patient enrollment
GlobeNewswire · 08/19 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PSTI. Analyze the recent business situations of Pluristem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PSTI stock price target is 16.10 with a high estimate of 25.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 2.36M
% Owned: 9.22%
Shares Outstanding: 25.55M
TypeInstitutionsShares
Increased
10
621.67K
New
32
72.59K
Decreased
9
418.25K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.88%
Pharmaceuticals & Medical Research
-0.82%
Key Executives
Chairman/Executive Director
Zalman Aberman
President/Chief Executive Officer/Director
Yaky Yanay
Chief Financial Officer/Treasurer/Secretary
Chen Franco-Yehuda
Lead Director/Independent Director
Doron Shorrer
Independent Director
Isaac Braun
Independent Director
Mark Germain
Independent Director
Moria Kwiat
Independent Director
Issac Braun
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PSTI
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.